GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
05 déc. 2023 09h05 HE
|
GRI Bio, Inc.
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant...
Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus
04 déc. 2023 09h00 HE
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
27 nov. 2023 08h35 HE
|
GRI Bio, Inc.
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to...
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
27 nov. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, Chief Financial Officer and Co-Chief Executive...
Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer
17 nov. 2023 08h00 HE
|
Serina Therapeutics, Inc.
Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a...
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
15 nov. 2023 08h05 HE
|
GRI Bio, Inc.
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are...
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
14 nov. 2023 09h00 HE
|
GeoVax, Inc.
Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results
13 nov. 2023 09h00 HE
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
13 nov. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potential dual coronavirus-norovirus oral antiviralDosing expected to begin later this year in Phase 2a human...
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q3 2023 Results
09 nov. 2023 14h45 HE
|
Harvard Apparatus Regenerative Technology, Inc.
HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“HRGN” or the “Company”), a clinical-stage biotechnology company developing the...